LC-MS Medical Devices for Laboratory Developed Tests
Brochures and specifications | 2020 | Thermo Fisher ScientificInstrumentation
Liquid chromatography–mass spectrometry (LC–MS) has emerged as a powerful complementary technology to conventional chemistry and immunoassays in clinical diagnostics. By delivering high specificity, rapid analysis and extended analyte coverage while reducing cost per sample and sample volume, LC–MS enables laboratories to develop in-house assays (LDTs) with improved confidence and operational efficiency.
This document presents a comprehensive portfolio of in vitro diagnostic (IVD)-compliant LC–MS medical devices and software solutions by Thermo Scientific designed for laboratory-developed tests. The goals are to replace expensive random-access immunoassays with cost-effective batch LC–MS workflows, meet varying sensitivity and throughput requirements, and integrate seamlessly with laboratory information systems (LIS).
A batch testing approach is employed using high-pressure liquid chromatography coupled to tandem mass spectrometry (LC–MS/MS). Quantitative assays rely on targeted selected reaction monitoring (SRM) to measure clinically relevant analytes. Data acquisition and processing are managed via dedicated software that automates method setup, sample queueing, data review and reporting.
Analytical demonstrations included steroid hormones (e.g., estrone, testosterone) and immunosuppressants (e.g., cyclosporin A, tacrolimus) at low nanogram levels. Mass spectra exhibited clear quantifier and qualifier transitions with high relative abundances and excellent mass resolution. The systems delivered fast SRM cycle times, stable performance over extended runs and reproducible results across instruments.
Continued adoption of LC–MS for routine clinical assays will drive further automation, higher throughput and expanded analyte coverage. Integration with digital laboratory ecosystems and advanced data analytics will enable personalized medicine, real-time monitoring and more robust decision support. Regulatory frameworks are also evolving to streamline IVD-compliant LC–MS assay deployment.
The Thermo Scientific portfolio provides a fully integrated solution for in-house clinical testing by LC–MS. It combines sensitive instrumentation, dedicated software and robust connectivity to enable laboratories to develop and validate reliable, cost-effective LDTs that meet stringent IVD requirements and support a wide range of clinical applications.
LC/MS, LC/MS/MS, LC/QQQ
IndustriesClinical Research
ManufacturerThermo Fisher Scientific
Summary
Significance of the topic
Liquid chromatography–mass spectrometry (LC–MS) has emerged as a powerful complementary technology to conventional chemistry and immunoassays in clinical diagnostics. By delivering high specificity, rapid analysis and extended analyte coverage while reducing cost per sample and sample volume, LC–MS enables laboratories to develop in-house assays (LDTs) with improved confidence and operational efficiency.
Objectives and study overview
This document presents a comprehensive portfolio of in vitro diagnostic (IVD)-compliant LC–MS medical devices and software solutions by Thermo Scientific designed for laboratory-developed tests. The goals are to replace expensive random-access immunoassays with cost-effective batch LC–MS workflows, meet varying sensitivity and throughput requirements, and integrate seamlessly with laboratory information systems (LIS).
Methodology
A batch testing approach is employed using high-pressure liquid chromatography coupled to tandem mass spectrometry (LC–MS/MS). Quantitative assays rely on targeted selected reaction monitoring (SRM) to measure clinically relevant analytes. Data acquisition and processing are managed via dedicated software that automates method setup, sample queueing, data review and reporting.
Instrumentation
- Vanquish MD HPLC system: dual solvent channels, ultra-precise flow control for robust separation
- TSQ Quantis MD Series mass spectrometer: triple-stage quadrupole with Active Ion Management (AIM+) for routine quantitation
- TSQ Altis MD Series mass spectrometer: enhanced sensitivity variant with optimized ion optics and high-capacity transfer tube
- OptaMax NG atmospheric pressure ionization source: automated gas/voltage connection for ESI or APCI operation
- TraceFinder LDT software: integrated quantitation, batch processing, user permissions and audit trails
- TSQ Series II Altis MD and Quantis MD Software: tuning, calibration and method development environment
- B-Link Universal LIS/LIMS Connector: middleware for bidirectional communication using ASTM-1394-91 and ASTM-1381-95 standards
Key results and discussion
Analytical demonstrations included steroid hormones (e.g., estrone, testosterone) and immunosuppressants (e.g., cyclosporin A, tacrolimus) at low nanogram levels. Mass spectra exhibited clear quantifier and qualifier transitions with high relative abundances and excellent mass resolution. The systems delivered fast SRM cycle times, stable performance over extended runs and reproducible results across instruments.
Benefits and practical applications
- Superior specificity and selectivity reduce false positives/negatives compared to immunoassays
- High throughput and fast turnaround meet clinical laboratory demands
- Multiplexed detection of multiple analytes in a single run enhances flexibility
- Lower operational costs through batch testing and reduced consumables
- IVD compliance with ISO 13485 and FDA 21 CFR 820 standards
- Risk control via validated workflows, certified service engineers and audit-ready software
- Seamless LIS integration minimizes manual data entry and accelerates result reporting
Future trends and applications
Continued adoption of LC–MS for routine clinical assays will drive further automation, higher throughput and expanded analyte coverage. Integration with digital laboratory ecosystems and advanced data analytics will enable personalized medicine, real-time monitoring and more robust decision support. Regulatory frameworks are also evolving to streamline IVD-compliant LC–MS assay deployment.
Conclusion
The Thermo Scientific portfolio provides a fully integrated solution for in-house clinical testing by LC–MS. It combines sensitive instrumentation, dedicated software and robust connectivity to enable laboratories to develop and validate reliable, cost-effective LDTs that meet stringent IVD requirements and support a wide range of clinical applications.
References
- ASTM E1394-91: Standard Specification for Clinical Laboratory Data Interchange
- ASTM E1381-95: Standard Practice for Clinical Laboratory Information Systems
Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.
Similar PDF
Five reasons to implement LC-MS platforms for your laboratory developed tests
2020|Thermo Fisher Scientific|Technical notes
SMART NOTE 5 REASONS LC-MS Medical Devices for Laboratory Developed Tests Five reasons to implement LC-MS platforms for your laboratory developed tests Technological advancements in Liquid Chromatography (LC) coupled to Mass Spectrometry (MS) technology, especially in the last decade, have…
Key words
lis, lismedical, medicalcompliant, compliantlims, limsivd, ivdldts, ldtsdevices, devicesdiagnostic, diagnostictests, teststhermo, thermoaltis, altislaboratory, laboratoryldt, ldtscientific, scientificclass
Exemplary performance data for steroids
2020|Thermo Fisher Scientific|Technical notes
DATA SHEET LC-MS Medical Devices For In Vitro Diagnostic Use Exemplary performance data for steroids Analytical performance of clinically relevant compounds TSQ Quantis MD Triple-Stage Quadrupole Mass Spectrometer Vanquish MD HPLC | HESI | APCI Preface Liquid chromatography systems Intended…
Key words
utak, utakcalibrator, calibratorcustom, customquantis, quantistsq, tsqpass, passprepared, prepareddiff, difftestosterone, testosteroneseries, serieshesi, hesidiagnostic, diagnosticldt, ldtvanquish, vanquishvitro
Exemplary performance data for immunosuppressants
2020|Thermo Fisher Scientific|Technical notes
DATA SHEET LC-MS Medical Devices For In Vitro Diagnostic Use Exemplary performance data for immunosuppressants Analytical performance of clinically relevant compounds TSQ Quantis MD Triple-Stage Quadrupole Mass Spectrometer | Vanquish MD HPLC Preface Liquid chromatography systems Intended use: The Thermo…
Key words
pass, passqciii, qciiiqcv, qcvdiff, diffcyclosporin, cyclosporinsirolimus, sirolimuseverolimus, everolimustacrolimus, tacrolimusrsd, rsdcalibrator, calibratorimmunosuppressants, immunosuppressantsvanquish, vanquishtsq, tsqquantis, quantisrecipe
Quantitation of 22 fentanyl analog compounds with a TSQ Altis MD mass spectrometer
2023|Thermo Fisher Scientific|Applications
Technical note | 001734 Clinical research and toxicology Quantitation of 22 fentanyl analog compounds with a TSQ Altis MD mass spectrometer Authors Goal Stephanie Samra and Richard Gibson Demonstrate the speed and sensitivity of the Thermo Scientific™ TSQ Altis™ MD…
Key words
fentanyl, fentanylignore, ignorelinear, linearaltis, altisfluorobutyryl, fluorobutyrylmethoxyacetyl, methoxyacetylacryl, acrylnorcarfentanil, norcarfentanilvaleryl, valerylcyclopropyl, cyclopropylremifentanil, remifentanilfuranyl, furanyltsq, tsqbutyryl, butyrylcarfentanil